| Expression of c-erbB-2 proto-oncogene in extrahepatic cholangiocarcinoma and its clinical significance. | liver,cholangiocarcinoma, |
| Expression of E-cadherin and c-erbB-2/HER-2/neu oncoprotein in high-grade breast cancer. | breast, |
| Immunohistochemical study of the expression of HER-2/neu oncogene in ovarian lesions. | ovarian, |
| Expression of HER-2/neu oncogene has a direct relationship iwth the grade of bladder transitional cell carcinoma. | bladder, |
| Overexpression of HER-2/neu oncogene and transitional cell carcinoma of bladder. | bladder, |
| FOXP3 is a novel transcriptional repressor for the breast cancer oncogene SKP2. | breast, |
| PF00299804 is a highly effective inhibitor of both the wild-type ERBB2 and the gefitinib-resistant oncogenic ERBB2 mutation identified in lung cancer cells. | lung, |
| The combined immunodetection of AP-2alpha and YY1 transcription factors is associated with ERBB2 gene overexpression in primary breast tumors. | breast, |
| This study highlights the role of both AP-2alpha and YY1 transcription factors in ERBB2 oncogene overexpression in breast tumors.High ERBB2 expression may result either from gene amplification or from increased transcription factor levels. | breast, |
| Alterations of estrogen receptors, progesterone receptors and c-erbB2 oncogene protein expression in ductal carcinomas of the breast. | breast, |
| Significance of HER2 and C-MYC oncogene amplifications in breast cancer in atomic bomb survivors: associations with radiation exposure and histologic grade. | breast, |
| The protein product of the ERBB2 oncogene is overexpressed in 33.3% of small cell lung carcinomas and is associated with the presence of disseminated disease | lung, |
| [Prognostic value of ERBB2 amplification and protein expression in small cell lung cancer]. | lung, |
| MUC4 mucin interacts with and stabilizes the HER2 oncoprotein in human pancreatic cancer cells. | pancreatic, |
| Comparison of chromogenic in situ hybridisation with fluorescence in situ hybridisation and immunohistochemistry for the assessment of her-2/neu oncogene in archival material of breast carcinoma. | breast, |
| HER2 oncogenic function escapes EGFR tyrosine kinase inhibitors via activation of alternative HER receptors in breast cancer cells. | breast, |
| Her-2/neu oncogene and nuclear roundness variance were shown to be significant in the prediction of progression-free survival in prostate cancer. | prostate, |
| Long-term assessment of prostate cancer progression free survival: evaluation of pathological parameters, nuclear shape and molecular biomarkers of pathogenesis. | prostate, |
| The antidiabetic drug metformin suppresses HER2 (erbB-2) oncoprotein overexpression via inhibition of the mTOR effector p70S6K1 in human breast carcinoma cells. | breast, |
| Comprehensive immunohistochemical analysis of Her-2/neu oncoprotein overexpression in breast cancer: HercepTest (Dako) for manual testing and Her-2/neuTest 4B5 (Ventana) for Ventana BenchMark automatic staining system with correlation to results of fluorescence in situ hybridization (FISH). | breast, |